{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:41:00Z","timestamp":1762864860554},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1992,1,1]],"date-time":"1992-01-01T00:00:00Z","timestamp":694224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1992]]},"DOI":"10.1007\/bf00686318","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T09:20:14Z","timestamp":1101720014000},"page":"226-228","source":"Crossref","is-referenced-by-count":11,"title":["Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion"],"prefix":"10.1007","volume":"30","author":[{"given":"D.","family":"Khayat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Borel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Azab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Paraisot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Malaurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bouloux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"6254","volume":"47","author":"C Auclair","year":"1987","unstructured":"Auclair C, Pierre A, Voisin E, et al (1987) Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl) 9-hydroxy ellipticinium chloride, HCl. Cancer Res 47:6254?6261","journal-title":"Cancer Res"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000226797","volume":"47","author":"AU Buzdar","year":"1990","unstructured":"Buzdar AU, Hortobagyi GN, Espanza LT, et al (1990) Elliptinium acetate in metastatic breast cancer ? a phase II study. Oncology 47: 101?104","journal-title":"Oncology"},{"key":"CR3","first-page":"537","volume":"30","author":"R Fellous","year":"1989","unstructured":"Fellous R, Berger Y, Gouyette A (1989) Pharmacokinetic, disposition, and metabolic studies of 2-(diethylamino-2-ethyl)-9-hydroxy ellipticinium chloride in rats. Proc Am Assoc Cancer Res 30:537","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1073\/pnas.71.12.5078","volume":"71","author":"JB Pecq Le","year":"1974","unstructured":"Le Pecq JB, Dat-Xuong N, Gosse C, Paoletti C (1974) A new antitumoral agent: 9-hydroxy ellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proc Natl Acad Sci USA 71:5078?5082","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207?214","journal-title":"Cancer"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.1985.3.5.735","volume":"3","author":"JM Mondesir","year":"1985","unstructured":"Mondesir JM, Bidart JM, Goodman A, et al (1985) Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264 137) treatment: schedule dependency and relationship to hemolysis. J Clin Oncol 3:735?740","journal-title":"J Clin Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0006-2952(89)90060-9","volume":"38","author":"E Multon","year":"1989","unstructured":"Multon E, Riou JF, Lefevre D, Ahomadegbe JC, Riou G (1989) Topoisomerase II-mediated DNA cleavage activity induced by ellipticine in the human tumor cell line N 417. Biochem Pharmacol 38: 2077?2086","journal-title":"Biochem Pharmacol"},{"key":"CR8","first-page":"457","volume":"7","author":"M Piccart","year":"1989","unstructured":"Piccart M, Dodion P, Merle S, Sculier JP, Crespeigne N, Wery F (1989) Phase I trial with 9-OH-2-N-diethylaminoethyl ellipticinium chloride, hydrochloride (SR 95156B). Invest New Drugs 7:457","journal-title":"Invest New Drugs"},{"key":"CR9","first-page":"1404","volume":"48","author":"V Pierson","year":"1988","unstructured":"Pierson V, Pierre A, Pommier Y, Gros P (1988) Production of protein-associated DNA breaks by 10-diethylaminopropyl-amino-6-methyl-5H-pyrido[3?, 4?:4, 5]pyrrolo-[2, 3-g]-isoquinoline (BD 40) in cultured L1210 cells and in isolated nuclei. Comparison with other topoisomerase II inhibitors. Cancer Res 48:1404?1409","journal-title":"Cancer Res"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/bi00344a015","volume":"24","author":"Y Pommier","year":"1985","unstructured":"Pommier Y, Minford JK, Schwarts RE, Zwelling LA, Kohn KW (1985) Effects of the DNA intercalators 4?-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxy ellipticinium on topoisomerase II-mediated DNA strand cleavage and strand passage. Biochemistry 24:6410?6416","journal-title":"Biochemistry"},{"key":"CR11","first-page":"437","volume":"68","author":"J Rouess\u00e9","year":"1981","unstructured":"Rouess\u00e9 J, Huertas D, Sancho-Garnier H, et al (1981) 2-N-methyl-9-hydroxy ellipticine in treatment of metastatic breast cancer. Bull Cancer (Paris) 68:437?441","journal-title":"Bull Cancer (Paris)"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/jps.2600571019","volume":"57","author":"GH Svoboda","year":"1968","unstructured":"Svoboda GH, Poore GA, Montfort ML (1968) Alkaloids ofOchrosia maculata Jacq. (Ochrosia borbanica Gmel.): isolation of the alkaloids and study of the antitumor properties of 9-methoxy ellipticine. J Pharm Sci 57:1720?1725","journal-title":"J Pharm Sci"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00170864","volume":"7","author":"J Treat","year":"1989","unstructured":"Treat J, Greenspan A, Rahman A, McCabe MS, Byrne PJ (1989) Elliptinium: phase II study in advanced measurable breast cancer. Invest New Drugs 7:231?234","journal-title":"Invest New Drugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686318\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:10:52Z","timestamp":1554459052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1992]]}},"alternative-id":["BF00686318"],"URL":"https:\/\/doi.org\/10.1007\/bf00686318","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992]]}}}